China IND Requirements Overly Burdensome To Industry - Shanghai R&D Summit
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The pharmaceutical industry should lobby the Chinese government to relax requirements for IND approvals that discourage multinational companies from sponsoring clinical trials in China, according to Hutchison MediPharma Managing Director Samantha Du